NEURONETICS INC (STIM) 6.2 -0.04 (-0.64%)
6.2 -0.04 (-0.64%)
US64131A1051 - Common Stock
Fundamental Rating
Overall STIM gets a fundamental rating of 2 out of 10. We evaluated STIM against 221 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of STIM have multiple concerns. STIM is quite expensive at the moment. It does show a decent growth rate.
Profitability
Profitability Rating
STIM's Return On Assets of -30.62% is in line with the rest of the industry. The industry average Return On Assets is -19.67%.
The profitability ratios for STIM are negative, so there is not much use analyzing them.
The Piotroski-F score of STIM is 3.00. This is a low score and indicates issues in the health and profitability of STIM.
VS Industry
ROA (-30.62%) VS Industry: 43% outperformed.
-771.54
117.69
Valuation
Valuation Rating
With a price book ratio of 2.68, STIM is valued correctly.
Compared to an average industry price book ratio of 2.62, STIM is valued in line with its industry peers.
STIM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for STIM. No positive earnings are expected for the next year.
VS Industry
Price/Book (2.68) VS Industry: 49% outperformed.
1,098.53
0.06
Growth
Growth Rating
STIM shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.02%.
Measured over the past 5 years, STIM shows a quite strong growth in Revenue. The Revenue has been growing by 10.07% on average per year.
The Revenue is expected to grow by 14.64% on average over the next 5 years. This is quite good.
When comparing the Revenue growth rate of the last 5 years to the growth rate of the upcoming 5 years, we see that the growth is accelerating.
Based on estimates for the next 5 years, STIM will show a decrease in Earnings Per Share. The EPS will decrease by -2.27% on average per year.
The earnings per share for STIM have decreased strongly by -24.45% in the last year.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | N/A | N/A | -24.45% | -38.21% | -8.46% | 9.14% | -2.27% |
| Revenue | 10.07% | 1.57% | 11.02% | 13.07% | 15.76% | 17.73% | 14.64% |
Health
Health Rating
STIM has a Current Ratio of 4.02. This indicates that STIM is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 3.68 indicates that STIM has no problem at all paying its short term obligations.
STIM has a Current Ratio comparable to the industry average, which is at 3.69.
STIM has a Quick Ratio comparable to the industry average, which is at 2.91.
Compared to an average industry Debt to Equity Ratio of 0.09, STIM is more dependent on financing than its industry peers.
STIM has an Altman-Z score of -1.82. This is a bad value and indicates that STIM is not financially healthy and even has some risk of bankruptcy.
When comparing the Altman-Z score of STIM to the average industry Altman-Z score of 1.87, STIM is less financially healthy than its industry peers.
The Piotroski-F score of STIM is 3.00. This is a low score and indicates issues in the health and profitability of STIM.
VS Industry
Debt/Equity (0.43) VS Industry: 27% outperformed.
336.87
0.00
Quick Ratio (3.68) VS Industry: 60% outperformed.
0.06
31.22
Current Ratio (4.02) VS Industry: 57% outperformed.
0.13
31.22
Altman-Z (-1.82) VS Industry: 32% outperformed.
-105.06
71.69
Dividend
Dividend Rating
STIM does not give a dividend.
NEURONETICS INC6.2
NASDAQ:STIM (12/8/2022, 7:09:20 PM)-0.04 (-0.64%)
| GICS Sector | Health Care | ||
| GICS IndustryGroup | Health Care Equipment & Services | ||
| GICS Industry | Health Care Equipment & Supplies | ||
| Earnings (Last) | 11-08 2022-11-08/bmo | Earnings (Next) | 03-06 2023-03-06 |
| Ins Owners | 8.46% | Inst Owners | 63.6% |
| Market Cap | 168.77M | Analysts | 80 |
| PE | N/A | Fwd PE | N/A |
| PEG (NY) | N/A | PEG (5Y) | N/A |
| P/S | 2.72 | P/B | 2.68 |
| EV/EBITDA | N/A | ||
| Dividend Yield | N/A | Dividend Growth | N/A |
| DP | N/A | Ex-Date | N/A |
| EPS 1Y | -24.45% | EPS 3Y | N/A |
| EPS 5Y | N/A | EPS growth Q2Q | 9.68% |
| EPS Next Y | -38.21% | EPS Next 2Y | -8.46% |
| EPS Next 3Y | 9.14% | EPS Next 5Y | -2.27% |
| Revenue growth 1Y | 11.02% | Revenue growth 3Y | 1.57% |
| Revenue growth 5Y | 10.07% | Revenue growth Q2Q | 19.56% |
| Revenue Next Year | 13.07% | Revenue Next 2Y | 15.76% |
| Revenue Next 3Y | 17.73% | Revenue Next 5Y | 14.64% |
| Current Ratio | 4.02 | Quick Ratio | 3.68 |
| Altman-Z | -1.82 | F-Score | 3 |
| Debt/Equity | 0.43 | WACC | 9.92% |
| ROIC/WACC | N/A | ||
| ROA | -30.62% | ROE | N/A |
| ROICexgc | N/A | ROIC | N/A |
| PM | N/A | OM | N/A |
| Asset Turnover | 0.52 | ||
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA